menu

Assessing Key Factors in Prognosis, Monitoring, & Therapeutic Decision-Making for Disease Worsening in MS

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Battle of the Biomarkers: Assessing Key Factors in Prognosis, Monitoring, & Therapeutic Decision-Making for Disease Worsening in Multiple Sclerosis

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Over the past several years, the image of MS has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease. With many markers of progression still under investigation and therefore not included in modern guidelines, MS clinicians are left on their own to decide which factors should hold the most weight in influencing clinical decisions. In this “debate-themed” symposium originally held in conjunction with the 2023 ACTRIMS Forum, Drs Shin, Alvarez, and Oh advocate for their preferred disease indicators and why they are the future of successful MS disease management. In the absence of professional guidelines, these expert perspectives may deepen the understanding of exactly how and why these factors should be considered, improving clinicians’ ability to navigate and optimize available tools and strategies for their own patients.

  • Disclosure of Conflicts of Interest

    DR. SHIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Alexion, Bristol Myers Squibb (BMS), EMD Serono, Genentech, Horizon, Icometrix, Novartis
    SPEAKERS BUREAU: Alexion, BMS, EMD Serono, Genentech, Horizon, Novartis, Sanofi Genzyme (Sanofi) 

    DR. OH REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Biogen-Idec (Biogen), BMS, EMD Serono, Lilly, Novartis, Roche, Sanofi
    GRANTS/RESEARCH SUPPORT: Biogen, EMD Serono, Roche
    ADVISORY BOARD: Biogen, Novartis, Roche, Sanofi
    SPEAKERS BUREAU: Biogen, BMS, EMD Serono, Novartis, Roche, Sanofi

    DR. ALVAREZ REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    ADVISORY BOARD: Alexion, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Novartis, Sanofi, TG Therapeutics
    GRANTS/RESEARCH SUPPORT: Biogen, Genentech/Roche, Novartis, National Institutes of Health, National Multiple Sclerosis Society, Patient-Centered Outcomes Research Initiative, Rocky Mountain MS Center, TG Therapeutics

  • Target Audience

    This activity is intended for neurodegenerative disease specialists, general neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.

  • Learning Objectives

    • Assess the relative roles of existing and emerging predictors/indicators of disease progression to guide the prioritization of these factors in proactive assessment of patient changes
    • Appraise the utility of clinical and radiologic assessments of disease progression to select the most sensitive and clinically appropriate monitoring tools that will not disrupt current workflow
    • Evaluate published research and expert experience guiding initial and subsequent disease modifying therapy choices in patients with different MS presentations to optimize therapeutic decision-making and maximize patient outcomes
  • Accreditation and Credit Designation Statements

    This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

    PHYSICIAN CREDIT
    Purdue designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Over the past several years, the image of MS has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease. With many markers of progression still under investigation and therefore not included in modern guidelines, MS clinicians are left on their own to decide which factors should hold the most weight in influencing clinical decisions. In this “debate-themed” symposium originally held in conjunction with the 2023 ACTRIMS Forum, Drs Shin, Alvarez, and Oh advocate for their preferred disease indicators and why they are the future of successful MS disease management. In the absence of professional guidelines, these expert perspectives may deepen the understanding of exactly how and why these factors should be considered, improving clinicians’ ability to navigate and optimize available tools and strategies for their own patients.

  • Disclosure of Conflicts of Interest

    DR. SHIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Alexion, Bristol Myers Squibb (BMS), EMD Serono, Genentech, Horizon, Icometrix, Novartis
    SPEAKERS BUREAU: Alexion, BMS, EMD Serono, Genentech, Horizon, Novartis, Sanofi Genzyme (Sanofi) 

    DR. OH REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Biogen-Idec (Biogen), BMS, EMD Serono, Lilly, Novartis, Roche, Sanofi
    GRANTS/RESEARCH SUPPORT: Biogen, EMD Serono, Roche
    ADVISORY BOARD: Biogen, Novartis, Roche, Sanofi
    SPEAKERS BUREAU: Biogen, BMS, EMD Serono, Novartis, Roche, Sanofi

    DR. ALVAREZ REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    ADVISORY BOARD: Alexion, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Novartis, Sanofi, TG Therapeutics
    GRANTS/RESEARCH SUPPORT: Biogen, Genentech/Roche, Novartis, National Institutes of Health, National Multiple Sclerosis Society, Patient-Centered Outcomes Research Initiative, Rocky Mountain MS Center, TG Therapeutics

  • Target Audience

    This activity is intended for neurodegenerative disease specialists, general neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.

  • Learning Objectives

    • Assess the relative roles of existing and emerging predictors/indicators of disease progression to guide the prioritization of these factors in proactive assessment of patient changes
    • Appraise the utility of clinical and radiologic assessments of disease progression to select the most sensitive and clinically appropriate monitoring tools that will not disrupt current workflow
    • Evaluate published research and expert experience guiding initial and subsequent disease modifying therapy choices in patients with different MS presentations to optimize therapeutic decision-making and maximize patient outcomes
  • Accreditation and Credit Designation Statements

    This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

    PHYSICIAN CREDIT
    Purdue designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 Feb 2024